Clinical Trial Details (PDF Generation Date :- Sat, 30 Sep 2023 10:06:07 GMT)

CTRI Number	CTRI/2019/01/017026 [Registered on: 10/01/2019] - **Trial Registered Prospectively**
Last Modified On	25/03/2023
Post Graduate Thesis	No
Type of Trial	Interventional
Type of Study	Vaccine Preventive
Study Design	Randomized, Parallel Group, Placebo Controlled Trial
Public Title of Study	To study effect of two vaccines in preventing spread of tuberculosis in persons living with new tuberculosis patients.
Scientific Title of Study	A Phase III, Randomized, Double-blind, three arm Placebo controlled Trial to Evaluate the Efficacy and Safety of two vaccines VPM1002 and Immuvac in Preventing Tuberculosis (TB) in Healthy Household Contacts of Newly Diagnosed Sputum Positive Pulmonary TB Patients.

Secondary IDs if Any

Secondary ID	Identifier
ICMR/ITRC/VAC/001/2018, Version 1.5, dated 3rd october 2018	Protocol Number

Details of Principal Investigator or overall Trial Coordinator (multi-center study)

Details of Principal Investigator	
Name	Manjula Singh
Designation	Scientist F
Affiliation	ICMR
Address	Indian Council of Medical Research V Ramalingaswami Bhawan P O Box No 4911 Ansari Nagar New Delhi - 110029 India New Delhi DELHI 110096 India
Phone	9868245793
Fax	01126588296
Email	drmanjulasb@gmail.com

Details Contact Person (Scientific Query)

Details Contact Person (Scientific Query)	
Name	Dr Manjula Singh
Designation	Scientist E
Affiliation	ICMR
Address	Indian Council of Medical Research V. Ramalingaswami Bhawan P O Box No 4911 Ansari Nagar New Delhi - 110029 India New Delhi DELHI 110029 India
Phone	9868245793
Fax	01126588896
Email	manjulas@icmr.org.in

Details Contact Person (Public Query)

Details Contact Person (Public Query)	
Name	Dr Manjula Singh
Designation	Scientist E
Affiliation	ICMR
Address	Indian Council of Medical Research V. Ramalingaswami Bhawan P O Box No 4911 Ansari Nagar New Delhi - 110029 India New Delhi DELHI

	110029 India
Phone	9868245793
Fax	01126588896
Email	manjulas@icmr.org.in

Source of Monetary or Material Support

Source of Monetary or Material Support
> Indian Council of Medical Research

Primary Sponsor

Primary Sponsor Details	
Name	Indian Council of Medical Research
Address	Indian Council of Medical Research Ansari Nagar New Delhi 110029 India
Type of Sponsor	Research institution

Details of Secondary Sponsor

Name	Address
NIL	NIL

Countries of Recruitment

List of Countries
India

Sites of Study

Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
Prof Randeep Guleria	All India Institute of Medical Science	Ansari Nagar, New Delhi -110029 New Delhi DELHI	9810184738 director.aiims@gmail.com
Dr Sindu Joshi	Bhagwan Mahavir Medical Research Centre	Plot No. 10-1- 1, AC Guards, Masab Tank, Hyderabad, Telangana 500004 Hyderabad ANDHRA PRADESH	9391099991 dr_sindhu@yahoo.com
Dr Samiran Panda	National AIDS Research Institute	Plot No 73, G-block, M I D C, Bhosari, Pune, Maharashtra 411026 Pune MAHARASHTRA	9830908475 director@nariindia.org
Dr Srikanth Tripathy	National Institute for Research in Tuberculosis and Madurai Unit	No. 8/1-2, Mayor Sathyamoorthy Street, Korukkupet, Chetpet, Chennai, Tamil Nadu 600031 Chennai TAMIL NADU	9506779797 directornirt@nirt.res.in
Dr Rohit Sarin	National Institute of Tuberculosis and Respiratory Diseases	Sri Aurobindo Marg, New Delhi -110030 New Delhi DELHI	9999971557 r.sarin@nitrd.nic.in
Dr N Somashekar	National Tuberculosis Institute	8, Avalon, Bellary Rd, Near Cauvery Theatre, Guttahalli, Bengaluru, Karnataka 560003 Bangalore KARNATAKA	08023441192 nti@ntiindia.org.in
Dr Sanghamitra Pati	Regional Medical Research Centre	Nandankanan Rd, SamantaVihar, Gajapati Nagar, Bhubaneswar, Odisha 751017	9437093306 drsanghamitra12@gmail.com

		Gajapati ORISSA	

Details of Ethics Committee

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
AIIMS Bhubaneswar IEC	Approved	13/05/2019	No
AIIMS Delhi EC	Submittted/Under Review	No Date Specified	Yes
BMMRC Hyderabad EC	Approved	10/12/2018	No
Ethics Commitee RMRC Bhubaneswar	Approved	04/01/2019	No
Ethics Committee NIRT Chennai	Approved	05/12/2018	No
Madurai Medical College& Govt Rajaji Hosp, IEC	Approved	16/06/2020	No
Medicity Ethics Committee	Approved	11/07/2020	No
NARI Pune EC	Approved	29/05/2018	Yes
NITRD Delhi EC	Approved	08/01/2019	No
NTI Bangalore EC	Approved	31/01/2019	No
SCB Medical College&Hosp_IEC	Approved	07/02/2020	No
StJohns Medical College and Hospital IEC	Approved	07/08/2020	No

Regulatory Clearance Status from DCGI

Status	Date
Approved/Obtained	20/12/2018

Health Condition / Problems Studied

Health Type	Condition
Healthy Human Volunteers	Healthy Household Contacts of Newly Diagnosed Sputum Positive Pulmonary Tuberculosis Patients.

Intervention / Comparator Agent

Type	Name	Details
Intervention	VPM1002	The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis rBCG?ureC: Hly+, freeze-dried/lyophilized and standardized to number of viable mycobacteria (colony forming units; CFU) per application. Frequency: 0.1ml intradermal single dose
Intervention	IMMUVAC	Immuvac is a heat killed suspension of Mycobacterium w, a non-pathogenic, cultivable atypical mycobacterium. Frequency and dose: 1st dose: 0.2ml intradermal in two divided doses 2nd dose: 0.1ml intradermal after 4 weeks
Comparator Agent	Placebo	Aqueous solution containing thiomerosal (0.1 mg/ml), sodium chloride (pyrogen free – 9

		mg/ml) and water for injection (q.s. to 1.0 ml) . This investigational product is supplied by Cadila Pharmaceuticals, Ahmedabad, India.

Inclusion Criteria

Inclusion Criteria	
Age From	6.00 Year(s)
Age To	99.00 Year(s)
Gender	Both
Details	i. Healthy household contacts age ? 6 years at the time of enrollment. ii. No evidence of active TB disease during screening – Normal chest radiograph with no abnormalities and no bacteriological positivity by smear testing for M.tb iii. Female participants who are currently using reliable methods of contraception (barrier methods and intrauterine contraceptive device), with a negative urine pregnancy test during screening and agree to informed compliance of contraceptive method until at least 4 months post-vaccination. iv. The participant must be able and willing to comply with the study protocol, available and willing to complete all the study assessments and must have signed an Informed Consent Form. v. Participant agrees to stay in contact with the study site for the duration of the study, and provide updated and an alternate contact information. vi. Has general good health, as confirmed through medical history and medical evaluation (which includes physical examination and laboratory tests).

Exclusion Criteria

Exclusion Criteria	
Details	i. Any chronic febrile illness with oral temperature > 100°F on the day of randomization. ii. Prior or present anti-TB treatment iii. Any laboratory abnormalities (haematological and biochemical), at the time of screening, which is of clinical significance as determined by the Investigator. iv. Pregnant and / or lactating female participants. v. Presence of any illness requiring short hospital referral (temporary exclusion). vi. Reactive serology for HIV. vii. Any confirmed or suspected immunodeficient condition based on medical history and physical examination and a family history of congenital or hereditary immunodeficiency. viii. History of chronic renal failure/dialysis, silicosis, gastrectomy, jejunoileal bypass, solid organ transplantation such as renal or cardiac transplants, carcinoma of the head and neck, and disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic inflammatory conditions, psychiatric, occupational problems that make it unlikely the volunteer will comply with the protocol as determined by the local investigator. ix. History of previous administration of experimental MTB vaccines. x. History of administration of any immunoglobulins, any immunotherapy (antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids use) and/or any blood products within the 3 months preceding study vaccination, or planned future administrations during the study period. Participants on inhaled/topical steroids may be permitted to participate in the study. xi. Participation in any clinical trial within 3 months prior to and/or planned concurrent participation in another interventional clinical trial at any point throughout the entire timeframe for this study. xii. History of allergic reactions or anaphylaxis to any vaccine or

	component of the vaccine. xiii. Presence of any severe systemic/autoimmune disorders as determined by medical history and / or physical examination/ or lab investigations at the time of screening, which in the judgment of the Investigator would compromise the participant's health or is likely to result in nonconformance to the protocol or a participant's ability to give written informed consent/assent.

Method of Generating Random Sequence	Stratified block randomization
Method of Concealment	Pre-numbered or coded identical Containers
Blinding/Masking	Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

Primary Outcome

Outcome	Timepoints
To compare the percentage of confirmed TB cases (PTB and EPTB) as per RNTCP guidelines in the vaccinated and placebo groups from 2 months after first dose of vaccine till 38 months follow-up period (VPM1002, Immuvac and Placebo).	1 year, 2 year and 3 year post-vaccination.

Secondary Outcome

Outcome	Timepoints
Number of participants developing LTBI, adverse events, protection from all types of TB and Immune Response to Vaccines.	LTBI-6 months, Adverse events-after vaccination till end of study period. Immune Response-day 0, 2 months, 6 months, and at the time of deveopment of TB.

Target Sample Size	**Total Sample Size=**12000 **Sample Size from India=**12000 **Final Enrollment numbers achieved (Total)=**Applicable only for Completed/Terminated trials **Final Enrollment numbers achieved (India)=**Applicable only for Completed/Terminated trials
Phase of Trial	Phase 3
Date of First Enrollment (India)	25/01/2019
Date of First Enrollment (Global)	No Date Specified
Estimated Duration of Trial	**Years=**3 **Months=**2 **Days=**0
Recruitment Status of Trial (Global)	Closed to Recruitment of Participants
Recruitment Status of Trial (India)	Closed to Recruitment of Participants
Publication Details	None.
Brief Summary	This is a a Phase III, Randomized, Double-blind, Placebo controlled Trial to Evaluate the Efficacy and Safety of VPM1002 and Immuvac Vaccines in Preventing Tuberculosis (TB) in Healthy Household Contacts of Newly Diagnosed Sputum Positive Pulmonary TB Patients, sponsored by ITRC, ICMR. Approximately12000 healthy household contacts of newly diagnosed PTB patients at six states (sites and sub-sites) in India. The primary objective of the study is to evaluate the efficacy of VPM1002 and Immuvac by comparing the reduction in incidence of TB over 3-year period among Indian healthy household contacts of newly diagnosed sputum positive PTB patients vaccinated with VPM1002 and Immuvac in comparison to placebo. The secondary objectives include to evaluate the efficacy of VPM1002 and Immuvac in prevention of LTBI in healthy household contacts of newly diagnosed sputum positive PTB patients in comparison to placebo [at 3 sites]; to evaluate the safety of VPM1002 and Immuvac in Indian healthy household contacts; and

to evaluate the Immunogenicity of VPM1002 and Immuvac in healthy household contacts as compared to placebo against tuberculosis [at 3 sites]. Interim analysis will be done at the time when 80 incident TB cases are observed in the trial or 50% of recruitment is completed, whichever is earlier. Final analysis will be done at the time when 160 incident TB cases are observed in the trial or end of follow up period whichever is earlier.